Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates
DERM•Journey Medical's third-quarter revenue rose 8% year over year to $19 million, below the $20.32 million consensus estimate. Net loss narrowed to $1.3 million from $2.3 million, while Emrosi revenue increased 84%.
1. Quarterly results
Journey Medical reported third-quarter revenue of $19 million, up 8% year over year but below the $20.32 million analyst consensus. Net loss narrowed to $1.3 million from $2.3 million a year earlier, and loss per share was $0.05.
2. Emrosi demand
Emrosi revenue rose 84% year over year, driven by higher prescription demand and improved reimbursement. The company said growth in unique prescribers and strong refill trends also contributed, and expects an expanded sales force and formulary wins to support further adoption.
